

September 26, 2002

To Whom It May Concern

Company: Taisho Pharmaceutical Co.,Ltd.
Representative: Akira Uehara, President
(First Section of TSE: Code 4535)
Contact: Takashi Shibata, Manager
Public Relations Section
(Tel: 81-3-3985-1115)

Establishment of Taisho Toyama Pharmaceutical

Taisho Pharmaceutical announces that it will establish a new sales and marketing company, Taisho Toyama Pharmaceutical Co., Ltd., on October 8, 2002, based on agreement with Toyama Chemical Co., Ltd of September 9, 2002. The new company will be a consolidated subsidiary of Taisho Pharmaceutical.

<Outline of the new sales and marketing company>

Corporate name:	Taisho Toyama Pharmaceutical Co., Ltd.
Representative:	
Chairman	Katsuhiko Nakano (Toyama, President and CEO)
President	Akira Uehara (Taisho, President)
Address of Head Office:	25-1, Takata 3-chome, Toshima-ku, Tokyo
Business Description:	Sales and promotion of prescription drugs
Fiscal year end:	March
Employees:	Approximately 1,300 (includes 1,000 of Medical Representatives) All the 1,300 people are transferred personnel for the time being.
Paid-in capital:	¥ 500 millions
Shareholders' equity:	¥ 1 Billions
Shares Outstanding:	10,000 shares
Shareholders:	Taisho Pharmaceutical (5,500 shares; 55%) Toyama Chemical (4,500 shares; 45%)
Start of Operation:	April 2003

Besides, on September 25, 2002, Taisho accepted Toyama Chemical's allocation of new shares to a third party in accordance with capital alliance agreement with Toyama. Please refer our press release dated September 9, 2002, for details.